| 43.92 0.04 (0.09%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.78 | 1-year : | 55.81 |
| Resists | First : | 45.19 | Second : | 47.79 |
| Pivot price | 43.55  |
|||
| Supports | First : | 41 | Second : | 34.11 |
| MAs | MA(5) : | 43.35  |
MA(20) : | 43.81 |
| MA(100) : | 42.63 |
MA(250) : | 49.38 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 57.8 |
D(3) : | 49.2 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 72.28 | Low : | 34.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NVO ] has closed below upper band by 42.5%. Bollinger Bands are 48% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 44.84 - 45.02 | 45.02 - 45.17 |
| Low: | 43.32 - 43.54 | 43.54 - 43.73 |
| Close: | 43.55 - 43.9 | 43.9 - 44.2 |
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Mon, 15 Jun 2026
Goldman Sachs Holds Firm On Novo Nordisk (NYSE: NVO) $47 Target After Healthcare Conference Meeting - foreignpolicyjournal.com
Mon, 15 Jun 2026
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Mon, 15 Jun 2026
Novo Nordisk: The Danish Empire Strikes Back (NYSE:NVO) - Seeking Alpha
Mon, 15 Jun 2026
Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan - Stock Titan
Mon, 15 Jun 2026
Novo Nordisk A/S - share repurchase programme - Yahoo Finance Singapore
Sat, 13 Jun 2026
Novo-Nordisk A/S (NVO) Stock Forum and Discussion - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,350 (M) |
| Shares Float | 3,190 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 22,680 (K) |
| Shares Short P.Month | 14,000 (K) |
| EPS | 4.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.07 |
| Profit Margin | 37.2 % |
| Operating Margin | 61.5 % |
| Return on Assets (ttm) | 19.2 % |
| Return on Equity (ttm) | 71.4 % |
| Qtrly Rev. Growth | 24 % |
| Gross Profit (p.s.) | 81.4 |
| Sales Per Share | 97.85 |
| EBITDA (p.s.) | 51.9 |
| Qtrly Earnings Growth | 67 % |
| Operating Cash Flow | 118,460 (M) |
| Levered Free Cash Flow | -12,040 (M) |
| PE Ratio | 10.38 |
| PEG Ratio | 3.2 |
| Price to Book value | 6.2 |
| Price to Sales | 0.44 |
| Price to Cash Flow | 1.24 |
| Dividend | 1.26 |
| Forward Dividend | 0 |
| Dividend Yield | 2.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|